肥胖患者预防及治疗静脉血栓栓塞症抗凝策略的研究进展  

Research progress on anticoagulation strategies for prevention and treatment of venous thromboembolism in patients with obesity

作　　者：刘俊杰 唐博[1] LIU Jun-jie;TANG Bo(Department of Vascular Surgery,Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院血管外科,重庆400010

出　　处：《局解手术学杂志》2023年第11期933-937,共5页Journal of Regional Anatomy and Operative Surgery

基　　金：国家自然科学基金(81400348);重庆医科大学附属第二医院“宽仁英才”项目。

摘　　要：肥胖(BMI≥30 kg/m^(2))已被证实为静脉血栓栓塞症(VTE)的独立危险因素,且肥胖程度和VTE发生风险呈显著正相关。已有研究表明,肥胖可能影响VTE患者的抗凝策略,而抗凝是VTE预防及治疗的关键,但固定剂量的抗凝策略对肥胖患者并不都合理。随着我国肥胖发病率的逐年上升,肥胖患者预防或治疗VTE的抗凝策略需要重点关注。因此,本文依据现有最新的循证医学证据,就肥胖这类特殊人群如何预防及治疗VTE的进展作一综述,以期为临床合理用药提供更多参考依据。Obesity(with BMI≥30 kg/m^(2)) has been proven to be an independent risk factor for venous thromboembolism(VTE),and the degree of obesity is significantly positively correlated with the risk of VTE.Studies have shown that obesity may affect the anticoagulation strategy of VTE patients.Anticoagulation is the key to the prevention and treatment of VTE,but the fixed-dose anticoagulation strategy is not always reasonable for obese patients.With the increasing incidence of obesity in China,the anticoagulation strategies for the prevention or treatment of VTE in obese patients need to be focused on.Therefore,based on the latest evidence-based medical evidence,this article reviews the development of anticoagulation strategies on how to prevent and treat VTE in obese patients,in order to provide more references for the rational use of drugs in clinical practice.

关 键 词：静脉血栓栓塞症 肥胖 抗凝 低分子肝素 新型直接口服抗凝药 

分 类 号：R543.6[医药卫生—心血管疾病]